Literature DB >> 18499335

Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.

Felix K-H Chun1, Nazareno Suardi, Umberto Capitanio, Claudio Jeldres, Sascha Ahyai, Markus Graefen, Alexander Haese, Thomas Steuber, Andreas Erbersdobler, Francesco Montorsi, Hartwig Huland, Pierre I Karakiewicz.   

Abstract

BACKGROUND: The rate of insignificant prostate cancer (IPCa) is increasing.
OBJECTIVES: To examine three end points in patients with a single, positive core and no high-grade prostate cancer (PCa) at biopsy, namely (1) rate of clinical IPCa at radical prostatectomy (RP), defined as organ-confined PCa with a Gleason score of 6 or lower and tumor volume<0.5 cc; (2) rate of pathologically unfavorable PCa at RP (Gleason 7-10 or non-organ-confined disease); and (3) ability to predict either insignificant or unfavorable PCa at RP. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 209 men with one positive biopsy core showing Gleason 6 or lower. MEASUREMENTS: : Detailed clinical and RP data were used in multivariable logistic regression models. Their bias-corrected accuracy estimates were quantified using the area under the curve (AUC) method. RESULTS AND LIMITATIONS: At RP, IPCa was present in 28 patients (13.4%) and pathologically unfavorable PCa, defined as Gleason 7 or higher or non-organ-confined PCa, was reported in 70 (33.5%) of 209 men; when Gleason 8 or higher or non-organ-confined PCa was considered, the proportion fell to 11%. Our multivariable models predicting different categories of pathologically unfavorable PCa at RP had an accuracy rate between 56% and 68% for predicting IPCa at RP versus 65.1% to 66.1% and 61.7% for the IPCa nomograms of Kattan et al and Nakanishi et al, respectively. Our data are not applicable to screening because they originate from a referral population.
CONCLUSIONS: Despite highly favorable biopsy features, between 11% and 33% of men had unfavorable PCa at RP and only a minority (13.4%) had pathologically confirmed IPCa. Neither clinically insignificant nor pathologically unfavorable features could be predicted with sufficient accuracy for clinical decision making.

Entities:  

Mesh:

Year:  2008        PMID: 18499335     DOI: 10.1016/j.eururo.2008.04.099

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  Low-risk prostate cancer and low testosterone: what are the acceptable alternatives?

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

Review 2.  [Prostate cancer: an update].

Authors:  M Hohenfellner
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

3.  Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.

Authors:  John W Davis; John F Ward; Curtis A Pettaway; Xuemei Wang; Deborah Kuban; Steven J Frank; Andrew K Lee; Louis L Pisters; Surena F Matin; Jay B Shah; Jose A Karam; Brian F Chapin; John N Papadopoulos; Mary Achim; Karen E Hoffman; Thomas J Pugh; Seungtaek Choi; Patricia Troncoso; Christopher J Logothetis; Jeri Kim
Journal:  BJU Int       Date:  2015-07-04       Impact factor: 5.588

Review 4.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

5.  Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci.

Authors:  John W Davis; Jeri Kim; John F Ward; Xuemai Wang; Hiro Nakanishi; R Joseph Babaian; Patricia Troncoso
Journal:  BJU Int       Date:  2009-11-03       Impact factor: 5.588

Review 6.  [Role of lymph node dissection in prostate cancer].

Authors:  T Schlomm; C Börgermann; H Heinzer; H Rübben; H Huland; M Graefen
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

Review 7.  Current status of biomarkers for prostate cancer.

Authors:  Vicki M Velonas; Henry H Woo; Cristobal G dos Remedios; Stephen J Assinder
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.